Jury Awards $4.62B in Johnson & Johnson Talcum Powder Lawsuit

Share this content:
Jury Awards $4.62B in Johnson & Johnson Talcum Powder Lawsuit
Jury Awards $4.62B in Johnson & Johnson Talcum Powder Lawsuit

FRIDAY, July 13, 2018 (HealthDay News) -- A jury says Johnson & Johnson must pay $4.62 billion to 22 women who allege they developed ovarian cancer after using the company's Baby Powder and Shower to Shower brand talcum powder as part of their daily feminine hygiene routine.

The St. Louis jury announced their decision July 12 after weeks of hearing testimony and eight hours of deliberation. The award includes $550 million in compensatory damages and $4.14 billion in punitive damages, CNN reported. It's the largest such verdict against the company, which plans to file an appeal.

"Every verdict against Johnson & Johnson in this court that has gone through the appeals process has been reversed and the multiple errors present in this trial were worse than those in the prior trials which have been reversed," the company said in an official statement.

Johnson & Johnson faces thousands of similar lawsuits nationwide. Favorable verdicts have been awarded to plaintiffs in five of the cases, but those cases are in various stages of appeal, CNN reported.

More Information - AP News
More Information - American Cancer Society

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Deep Learning-Enhanced Device Detects Diabetic Retinopathy

Deep Learning-Enhanced Device Detects Diabetic Retinopathy

Device sensitivity/specificity 100/97.8 percent for vision-threatening diabetic retinopathy

Altered Gut Microbiome Seen in Patients With Active Lupus

Altered Gut Microbiome Seen in Patients With Active ...

Patients with lupus had fivefold greater representation of Ruminococcus gnavus

Combo Regimens Effective for Tx of Metastatic Renal Cell Cancer

Combo Regimens Effective for Tx of Metastatic Renal ...

Two large trials show benefits for pembrolizumab-axitinib and avelumab-axitinib versus sunitinib

is free, fast, and customized just for you!




Already a member?

Sign In Now »